- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01772199
Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
August 12, 2016 updated by: GlaxoSmithKline
Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
This is a randomized, parallel group, placebo-controlled study designed to assess whether GSK239512 can enhance lesion remyelination in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
Subjects with RRMS on stable background treatment with either Avonex (Interferon-beta1a) or Copaxone (Glatiramer Acetate) are eligible to participate.
Subjects will be randomized in a 1:1 ratio between placebo and GSK239512, and will continue to be managed with their current standard of care therapy (Copaxone or Avonex).
The total treatment period is 48 weeks, including a standard 4 week titration period and 44 week maintenance treatment period (which could be adapted to a 5-week titration and 43 week maintenance period, if needed).
Titration doses start at 10 micrograms (mcg) and increase up to 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week).
Subjects will be titrated to the maximum tolerated dose with the objective of titrating to the highest dose (80 mcg GSK239512), whenever possible, based on investigator judgement of tolerability.
The post-treatment follow-up period will be a minimum of 2 weeks in duration following the end of treatment at Week 48 or early withdrawal, as appropriate.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
131
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sofia, Bulgaria, 1431
- GSK Investigational Site
-
Sofia, Bulgaria, 1113
- GSK Investigational Site
-
Sofia, Bulgaria, 1309
- GSK Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- GSK Investigational Site
-
Edmonton, Alberta, Canada, T6G 1Z1
- GSK Investigational Site
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- GSK Investigational Site
-
-
Quebec
-
Gatineau, Quebec, Canada, J9J 0A5
- GSK Investigational Site
-
Montreal, Quebec, Canada, H3A 2B4
- GSK Investigational Site
-
-
-
-
-
Jihlava, Czech Republic, 586 33
- GSK Investigational Site
-
Olomouc, Czech Republic, 775 20
- GSK Investigational Site
-
Teplice, Czech Republic, 415 29
- GSK Investigational Site
-
-
-
-
-
Berlin, Germany, 10961
- GSK Investigational Site
-
Berlin, Germany, 12163
- GSK Investigational Site
-
Hamburg, Germany, 20249
- GSK Investigational Site
-
Hamburg, Germany, 22083
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Ulm, Baden-Wuerttemberg, Germany, 89073
- GSK Investigational Site
-
-
Bayern
-
Alzenau, Bayern, Germany, 63755
- GSK Investigational Site
-
Unterhaching, Bayern, Germany, 82008
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Koeln, Nordrhein-Westfalen, Germany, 50935
- GSK Investigational Site
-
Muenster, Nordrhein-Westfalen, Germany, 48149
- GSK Investigational Site
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01069
- GSK Investigational Site
-
Leipzig, Sachsen, Germany, 04103
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spain, 08036
- GSK Investigational Site
-
Barcelona, Spain, 08035
- GSK Investigational Site
-
Madrid, Spain, 28040
- GSK Investigational Site
-
Madrid, Spain, 28046
- GSK Investigational Site
-
Madrid, Spain, 28034
- GSK Investigational Site
-
Majadahonda (Madrid), Spain, 28222
- GSK Investigational Site
-
Malaga, Spain, 29010
- GSK Investigational Site
-
Sevilla, Spain, 41009
- GSK Investigational Site
-
-
-
-
-
Stockholm, Sweden, SE-141 86
- GSK Investigational Site
-
-
-
-
-
Donetsk, Ukraine, 83099
- GSK Investigational Site
-
Ivano-Frankivsk, Ukraine, 76008
- GSK Investigational Site
-
Kharkiv, Ukraine, 61068
- GSK Investigational Site
-
Kyiv, Ukraine, 04107
- GSK Investigational Site
-
Lutsk, Ukraine, 43005
- GSK Investigational Site
-
Lviv, Ukraine, 79010
- GSK Investigational Site
-
Poltava, Ukraine, 36024
- GSK Investigational Site
-
Vinnitsa, Ukraine, 21005
- GSK Investigational Site
-
-
-
-
-
London, United Kingdom, SE5 9RS
- GSK Investigational Site
-
London, United Kingdom, NW1 2BU
- GSK Investigational Site
-
Romford, United Kingdom, RM7 0AG
- GSK Investigational Site
-
Sheffield, United Kingdom, S10 2JF
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 to 50 years of age
- Diagnosed with a relapsing-remitting course of multiple sclerosis as defined by the appropriate McDonald criteria at the time of diagnosis.
- Diagnosis of RRMS made within approximately 10 years prior to the screening visit (as documented by year of diagnosis or duration of disease), and No physical manifestations of other forms of Multiple Sclerosis (MS) including signs of progression to secondary progressive MS (SPMS)
- Currently compliant with a stable dose regimen of Avonex (Interferon Beta1a) or Copaxone (Glatiramer Acetate) for management of MS for >= 1 year prior to the screening visit
- The occurrence of at least one of the following (within the year preceding the screen visit AND after >=2 months of stable treatment with Avonex OR Copaxone): a) 1 reported and/or documented relapse, OR b) 1 Gadolinium Enhanced (GdE) lesion on MRI
- Currently neurologically stable, in the investigator's judgment, and not actively experiencing or recovering from a recent relapse at the screening visit
- A Kurtzke Expanded Disability Status Scale (EDSS) score of 1 to 4.5 (inclusive) at the screening visit.
- Must agree not to participate in a clinical study involving another investigational drug or device throughout their participation in this study. Non-interventional study participation is allowed if the time involvement and scheduling will not interfere with compliance in this study in the opinion of the investigator
- A female subject is eligible to enter the study if she is a) Not pregnant or nursing, b) Of non-childbearing potential (i.e. women who have had a hysterectomy, are postmenopausal, which is defined as >2 years without menses [female subjects who have been post-menopausal for <2 years must be confirmed with Follicle Stimulating Hormone and estradiol levels], have both ovaries surgically removed or have current documented tubal ligation); or, c) Of childbearing potential and agrees to use the acceptable methods of birth control, for one month prior to the start of investigational product to 1 month after the last dose of investigational product.
- Informed Consent: Must be competent to understand the information given in the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved Informed Consent Form (ICF) and must sign the form prior to the initiation of any study procedures
Exclusion Criteria:
- MRI: Unable to undergo MRI scans (e.g. due to pacemaker, severe claustrophobia, hypersensitivity to contrast media), Lacks adequate venous access for administration of Gd-enhancing agent, or Findings on brain MRI scan indicating any clinically significant brain abnormality other than MS (e.g. damage associated with prior traumatic brain injury)
- Past and Concurrent Medical Conditions: a) History of severe and clinically significant CNS trauma with current sequelae (e.g. traumatic brain injury, spinal cord compression), b) Significant concurrent, uncontrolled medical condition or disease which in the opinion of the investigator could (e.g. significant psychiatric disorder, etc), affect the subjects' safety, impair the subject's reliable participation in the trial, impair the evaluation of the endpoints, or necessitate the use of medication not allowed by this protocol, c) History or presence of myelopathy due to spinal cord compression by disk or vertebral disease or chronic progressive myelopathy, d) Diagnosis of any type epilepsy, e) At risk of suicide, as indicated by: A documented history of attempted suicide or significant suicidal ideation during the 6 months preceding the screening visit, OR If in the investigator's judgment the subject is at risk of a suicide attempt based on the screen visit assessment, including the eC-SSRS, f) Presence of significant and routine sleep disturbance (severe insomnia, nocturnal wandering, confusion, disorientation, agitation, or vivid dreams) that has a negative impact on quality of life that, in the judgement of the investigator, may increase the risk of tolerability issues during dose escalation, g) Presence or history of hallucinations that, in the judgement of the investigator, may increase the safety risk to the subject, h) Known diagnosis or history consistent with positive human immunodeficiency virus (HIV)
- Past and Current Medications and Therapies: Have had treatment with the following to manage their MS: a) Within 1 year: fingolimod (e.g. Gilenya), Rebif (interferon beta1a), interferon beta1b (e.g. Betaseron), mycophenolate mofetil (e.g. CellCept), or Recently approved medication or formulation indicated for the management of MS. Consult with GlaxoSmithKline (GSK) Medical Monitor if there are specific questions regarding eligible treatments b) Within 2 years: natalizumab (e.g. Tysabri), alemtuzumab (e.g. Campath), daclizumab (e.g. Zenapax), rituximab (e.g. Rituxan), mitoxantrone (e.g. Novantrone), cladribine (e.g. Leustatin), or azathioprine (e.g. Imuran)
- Have used corticotropin to manage a relapse within 6 months prior to Screen Visit.
- Have had treatment with the following and were unable to discontinue and refrain from treatment for the specified time period and are not able to discontinue use throughout participation in the clinical trial: dalfampridine /fampridine (e.g. Ampyra) - 1 month prior to Screen Visit, nabiximols (e.g. Sativex) - 1 month prior to Screen Visit, amantadine (e.g. Symmetrel) - 3 months prior to Screen Visit, or leflunomide (e.g. Arava) - 1 year prior to Screen Visit
- Have used the following medications within the last 30 days or 5 half-lives (whichever is longer) prior to screening and are not able to discontinue use throughout participation in the clinical trial: Any CNS stimulants (e.g., modafinil, dexamphetamine, methylphenidate), Known potent P-glycoprotein inhibitors (e.g. itraconazole, ketoconazole, cyclosporin, loperamide, diltiazem, verapamil, spironolactone, quinidine, bepridil, quinine, carvedilol), Known potent inhibitors or inducers of the CYP3A4 enzyme (e.g., verapamil, ketoconazole, cimetidine, rifampin, modafinil), CNS-penetrant antihistamines (e.g. bromopheniramine, chlorpheniramine, clemastine, diphenhydramine, hyrdoxyzine),
- History of medically significant adverse effects (including allergic reactions and hypersensitivities) following treatment with: Histamine H3 receptor antagonist or inverse agonist, Gadolinium enhancing agent, Relapse medication: glucocorticoids (e.g., methylprednisolone) OR A known hypersensitivity to components of the investigational product, relapse medication, or Gadolinium enhancing agent.
- Electrocardiogram (ECG) showing a clinically significant abnormality at screening. Including a QT interval corrected using Bazett's and Fridericia's formulas (QTcB or QTcF) interval of >=450 msec or >=480 msec for patients with a Bundle Branch Block.
- Infectious Disease Status at Screening a) Subjects with no documented record of vaccination against Hepatitis B (primary and secondary immunization and booster) AND a positive test for hepatitis B surface antigen (HBsAg and Hepatitis B Core Antibody [IgM anti-HBc]), b) Subjects with serologic evidence of active Hepatitis C, as indicated by a positive Hepatitis C Virus(HCV) RNA test and anti-HCV antibody test
- Laboratory Values at Screening: Hematology: Total white cell count <2.0 x 109/L, Neutrophils <1.0 x 109/L, Platelets <75 x 109/L (If out of range, platelet count can be repeated to exclude platelet clumping), or Haemoglobin < 80 g/L.
- Screening clinical chemistry liver function test: Alanine aminotransferase (ALT) >2.0 x upper limit of normal (ULN), Aspartate aminotransferase (AST) >2.0 x ULN, Alkaline phosphatise (ALP) >1.5 x ULN, or Bilirubin >1.5 x ULN.
- Documented renal insufficiency or laboratory results indicative of renal insufficiency (due to risks associated with administration of Gadolinium based contrast agents to subjects with moderate to severe kidney disease): Estimated Creatinine Clearance (Cockroft-Gault) <60 mL/minute
- If known, or according to investigator judgement, subject is suspected of not being able to comply with the study protocol requirements. Contributing factors to this assessment by the investigator could be, but not limited to: job demands, substance abuse, alcoholism, drug dependency or psychological disorder
- Prior participation in a clinical trial or use of an investigational product for a non approved intervention: Prior use of an investigational drug for MS or a condition other than MS within 4 weeks or 5 half-lives (whichever is longer) prior to screening. The GSK Medical Monitor should be consulted to confirm eligibility
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GSK239512 Arm
GSK239512 once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
|
White to almost white, round tablets.
Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
|
Placebo Comparator: Placebo Arm
Placebo once daily orally
|
White to almost white, round tablets.
Once daily orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in gadolinium (Gd) enhanced (GdE) lesion magnetization transfer ratio (MTR) differences (calibrated to reference scan) from before enhancement to stable recovery (>=3 months post new GdE lesion)
Time Frame: Up to Week 48
|
A single Baseline magnetic resonance image (MRI) prior to randomization.
Following randomization, a total of 8 MRIs at approximate 6 week intervals: Week 6, Week 12, Week 18, Week 24, Week 30, Week 36, Week 42, Week 48.
Reference MRI: In order to accommodate variations in MTR images acquired using different scanners, the images must be normalized to eliminate intensity shifts and contrast variations.
For each scanner, images from a normal subject will be obtained and processed to serve as a calibration for each scanner prior to initiating scanning for subjects participating in the study
|
Up to Week 48
|
Mean change in Delta MTR lesion MTR differences (calibrated to reference scan) from before lesion appearance to stable recovery (>=3 months post lesion appearance)
Time Frame: Up to Week 48
|
A single Baseline MRI prior to randomization Following randomization, a total of 8 MRIs at approximate 6 week intervals: Week 6, Week 12, Week 18, Week 24, Week 30, Week 36, Week 42, Week 48.
Reference MRI: In order to accommodate variations in MTR images acquired using different scanners, the images must be normalized to eliminate intensity shifts and contrast variations.
For each scanner, images from a normal subject will be obtained and processed to serve as a calibration for each scanner prior to initiating scanning for subjects participating in the study
|
Up to Week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in T2 lesion MTR at Week 48
Time Frame: Baseline and Week 48
|
Baseline and Week 48
|
|
Cumulative new and enlarging Gd enhancing, T2 and Combined Unique Active lesions comparing placebo to GSK239512 treated subjects
Time Frame: Up to Week 48
|
Up to Week 48
|
|
Change from baseline at Week 48 in total brain volume, white matter volume and grey matter volume comparing placebo to GSK239512 treated subjects
Time Frame: Baseline and Week 48
|
Baseline and Week 48
|
|
Cumulative number of persistent black holes and new unenhancing T1 lesion counts comparing placebo to GSK239512 treated subjects over treatment duration up to Week 48
Time Frame: Up to Week 48
|
Up to Week 48
|
|
Proportion of new GdE lesions evolving into chronic (unenhancing) T1 lesions (black holes) comparing placebo to GSK239512 treated subjects over treatment duration up to Week 48
Time Frame: Up to Week 48
|
Up to Week 48
|
|
Mean change from baseline in overall cognitive impairment and cognitive domains comparing placebo to GSK239512 treated subjects
Time Frame: Baseline and Week 48
|
A cognitive battery (computerized battery) is included in this study to assess the impact, if any, on several cognitive functional domains.
The battery will be executed twice during the screen visit to familiarize the subject with the use of the tool
|
Baseline and Week 48
|
Comparison of Relapse Rates between placebo and GSK239512 treated subjects
Time Frame: Up to 50 Weeks
|
A relapse in this protocol is defined as: "patient-reported symptoms or objectively observed signs typical of an acute inflammatory demyelinating event in the central nervous system (CNS), current or historical".
It must occur in the absence of fever or infection and should - follow improvement from a previous relapse, occur at least 30 days following the onset of a previous relapse, and be persistent for at least 24 hours
|
Up to 50 Weeks
|
Comparison of Time to First Relapse between placebo and GSK239512
Time Frame: Up to 50 Weeks
|
A relapse in this protocol is defined as: "patient-reported symptoms or objectively observed signs typical of an acute inflammatory demyelinating event in the central nervous system (CNS), current or historical".
It must occur in the absence of fever or infection and should - follow improvement from a previous relapse, occur at least 30 days following the onset of a previous relapse, and be persistent for at least 24 hours
|
Up to 50 Weeks
|
Comparison of the proportion of subjects Relapse Free between placebo and GSK239512 treated subjects
Time Frame: Up to 50 Weeks
|
A relapse in this protocol is defined as: "patient-reported symptoms or objectively observed signs typical of an acute inflammatory demyelinating event in the central nervous system (CNS), current or historical".
It must occur in the absence of fever or infection and should - follow improvement from a previous relapse, occur at least 30 days following the onset of a previous relapse, and be persistent for at least 24 hours
|
Up to 50 Weeks
|
Proportion of subjects with sustained worsening of Expanded Disability Severity Scale (EDSS) over 3 months comparing placebo to GSK239512 treated subjects
Time Frame: Up to 48 Weeks
|
The EDSS is an assessment of disability specifically associated with Multiple Sclerosis.
The assessment will be captured in the medical records including the detailed assessment and scoring for each functional system and domain
|
Up to 48 Weeks
|
Mean change from baseline in the EDSS functional systems and a subset of component assessments comparing placebo to GSK239512 treated subjects
Time Frame: Up to 48 Weeks
|
The EDSS is an assessment of disability specifically associated with Multiple Sclerosis.
The assessment will be captured in the medical records including the detailed assessment and scoring for each functional system and domain
|
Up to 48 Weeks
|
Safety and tolerability as assessed by frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Up to Week 50
|
Up to Week 50
|
|
Safety and tolerability as assessed by percentage of subjects withdrawing due to AEs
Time Frame: Up to Week 50
|
Up to Week 50
|
|
Safety and tolerability as assessed by summary of suicide behavior and ideation risk as assessed by the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
Time Frame: Up to Week 50
|
Up to Week 50
|
|
Safety and tolerability as assessed by summary of suicide behavior and ideation risk as assessed by Possible Suicidality Related Adverse Event (PSRAE)
Time Frame: Up to Week 50
|
Up to Week 50
|
|
Safety and tolerability as assessed by change from baseline in clinical chemistry, hematology, and urinalysis parameters
Time Frame: Up to Week 50
|
Up to Week 50
|
|
Safety and tolerability as assessed by frequency of clinical chemistry, hematology, and urinalysis parameters of potential clinical concern
Time Frame: Up to Week 50
|
Up to Week 50
|
|
Safety and tolerability as assessed by change from baseline in blood pressure
Time Frame: Up to Week 50
|
Up to Week 50
|
|
Safety and tolerability as assessed by change from baseline in heart rate
Time Frame: Up to Week 50
|
Up to Week 50
|
|
Safety and tolerability as assessed by change from baseline in Electrocardiogram (ECG) parameters
Time Frame: Up to Week 50
|
Up to Week 50
|
|
Safety and tolerability as assessed by frequency of vital signs and ECG parameters of potential clinical concern
Time Frame: Up to Week 50
|
Up to Week 50
|
|
Trough concentration of GSK239512 at Week 4, Week 24, Week 36 and Week 48
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
Sparse Pharmacokinetics (PK) sampling for concentration of GSK239512 at Week 8
Time Frame: Pre-dose, and 30 minutes (15 min to 1 hour), 2 hours (1 to 4 hours) and 6 hours (4 to 8 hours) post dose
|
1 pre-dose and 3 post-dose samples.
No samples should be collected within 30 minutes of the previous sample
|
Pre-dose, and 30 minutes (15 min to 1 hour), 2 hours (1 to 4 hours) and 6 hours (4 to 8 hours) post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (Actual)
September 1, 2014
Study Completion (Actual)
September 1, 2014
Study Registration Dates
First Submitted
January 17, 2013
First Submitted That Met QC Criteria
January 17, 2013
First Posted (Estimate)
January 21, 2013
Study Record Updates
Last Update Posted (Estimate)
August 16, 2016
Last Update Submitted That Met QC Criteria
August 12, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 116477
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Individual Participant Data Set
Information identifier: 116477Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 116477Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 116477Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 116477Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 116477Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 116477Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 116477Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis, Relapsing-Remitting
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
-
Mitsubishi Tanabe Pharma CorporationCompletedRelapsing-remitting Multiple SclerosisCroatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States
Clinical Trials on GSK239512
-
GlaxoSmithKlineCompletedDementia | Mild Cognitive ImpairmentCanada
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedAlzheimer's DiseaseAustralia, Korea, Republic of, United Kingdom, Czechia
-
GlaxoSmithKlineCompletedAlzheimer's DiseaseBulgaria, Germany, Korea, Republic of, Russian Federation, United Kingdom, Chile, Czech Republic, Slovakia